BioWorld

Sep. 26, 2006

GPC Biotech Shares Jump On Prostate Cancer Study Results

House Committee Passes Bill For Biodefense Agency

NovaCardia Series B Raises $48M For Phase III CHF Bid

Other News To Note

Clinic Roundup

Fampridine-SR Data Sends Acorda Stock Through Roof

Shares in Acorda Therapeutics Inc. rocketed by more than 282 percent Monday on positive findings from a Phase III study of Fampridine-SR in multiple sclerosis. (BioWorld Today) Read More

BIO Midwest Event Brings Biotech, VCs To Cleveland

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 10, 2025.

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Red blood cells in an artery with cholesterol

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

BioWorld

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...

Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...